Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mechanism for RNA Activation in Duchenne Muscular Dystrophy

by | PRNewswire Asia

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a monogenic disease. Paired muscle biopsies reveal 3.5- to 5.3-fold increases in sarcolemmal...

PEA Powers Thailand's Sustainable Energy Future Through a Brand Built on Trust, Innovation, and Meaningful Impact

by | PRNewswire Asia

BANGKOK, Oct. 3, 2026 /PRNewswire/ — A trusted brand is built through every interaction, from the reliability of essential services to the way an organization responds when communities need it most. For the Provincial Electricity Authority (PEA), this principle...

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

by | PRNewswire Asia

SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ — Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or...

Agricultural Corporation Geumsan Insamju to Showcase Traditional Ginseng Liquor Craftsmanship at '2026 International Ginseng Trade Fair'

by | PRNewswire Asia

Food Master-certified liquor maker to present traditional production techniques and signature products to domestic and international buyers SEOUL, South Korea, Oct. 3, 2026 /PRNewswire/ — Agricultural Corporation Geumsan Insamju will take part in the...

Chiron Medical Group's October "Safeguarding Breast Health With Heart" Campaign: Integrating Breast Health into Daily Life

by | PRNewswire Asia

"Safeguarding Breast Health With Heart" HONG KONG, Oct. 2, 2026 /PRNewswire/ — As we enter Breast Cancer Awareness Month in October, Chiron Medical Group, together with its FemWell Women’s Health Centre and Chiron Breast Health Centre, is...

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

by | PRNewswire Asia

HONG KONG, Oct. 2, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes...